Table 2.

Long-term mortality and venous thromboembolic (VTE) outcomes of all patients with severe trauma enrolled into the da Vinci trial in Western Australia with complete data including hospitalization cost available for the study (N = 223)

Outcome	Filter group (n = 114)	Control group (n = 109)	P value#
All forms of VTE within 90 days of enrollment, no. (%)	22 (19.3)	15 (13.8)	0.267
Symptomatic PE within 90 days of enrollment, no. (%)	1 (0.9)	6 (5.5)	0.048
All forms of VTE beyond 90 days after enrollment, no. (%) (N = 198)	0 (0)	4 (4)	0.043
Symptomatic PE beyond 90 days after enrollment, no. (%) (N = 198)	0	2 (2)*	0.155
Symptomatic PE since enrollment with follow-up until March 4, 2022, no. (%) (N = 223)	1 (0.5)	8 (7.3)	0.014
Symptomatic PE since enrollment for those who could not be anticoagulated within 7 days of injury with follow-up until March 4, 2022, no. (%) (N = 72: 41 for the filter group, 31 for the control group)	0 (0)	6 (19.4)	0.005
Mean hospitalization cost up to day 90 after enrollment (standard deviation)** (N = 223), A$	140,112 (100,143)	121,124 (99,187)	0.040
Mean total hospitalization cost up to day 90 after enrollment for those who could not be anticoagulated within 7 days of injury (standard deviation)*** (N = 72), A$	138,280 (103,692)	132,254 (85,232)	0.941
Mortality beyond 90 days after enrollment, no. (%) (N = 198)	6 (6.1)	4 (4.0)	0.516

PE pulmonary embolism

*At 10 and 62 months and both patients had spinal cord injury with neurological deficits. ^#By chi-square or Mann–Whitney test. **The mean total hospitalization cost, including the costs of the filter and the procedures to insert and remove the filter, to prevent one symptomatic PE was A$284,820 when all patients were considered. ***The mean total hospitalization costs, including the costs of the filter and the procedures to insert and remove the filter, to prevent one symptomatic PE was A$1,205 when the filter was used only for patients who could not be anticoagulated within 7 days of injury